Search
                    Idiopathic Pulmonary Fibrosis Clinical Trials
A listing of 24  Idiopathic Pulmonary Fibrosis  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 24
        
                There are currently 24 active clinical trials seeking participants for Idiopathic Pulmonary Fibrosis research studies. The states with the highest number of trials for Idiopathic Pulmonary Fibrosis participants are California, Florida, Texas and Pennsylvania.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.
Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: University of Alabama at Birmingham, Birmingham, Alabama  +178 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
        
            
        
    
                
                                    A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
                                
            
            
        Recruiting
                            
            
                This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550.
The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/19/2025
            
            Locations: University of Alabama at Birmingham, Birmingham, Alabama  +370 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
        
            
        
    
                
                                    A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
                                
            
            
        Recruiting
                            
            
                The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Cohort 1 has com...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                08/08/2025
            
            Locations: University of Alabama at Birmingham, Birmingham, Alabama  +113 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
        
            
        
    
                
                                    A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/07/2025
            
            Locations: The University of Alabama at Birmingham, Birmingham, Alabama  +503 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
                                
            
            
        Recruiting
                            
            
                A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/05/2025
            
            Locations: WISPer site in Phoenix, AZ, Phoenix, Arizona  +7 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
                                
            
            
        Recruiting
                            
            
                Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/05/2025
            
            Locations: University of California San Francisco, San Francisco, California  +15 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
                                
            
            
        Recruiting
                            
            
                This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                07/31/2025
            
            Locations: Pulmonary Associates, PA, Mesa, Arizona  +29 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 85 years
            Trial Updated:
                07/09/2025
            
            Locations: The University of Alabama at Birmingham, Birmingham, Alabama         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
                                
            
            
        Recruiting
                            
            
                Background:
Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years.
Objective:
To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis.
Eligibility:
People aged 18 years and older with interstitial lung disease...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                07/09/2025
            
            Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina         
        
        
            Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
        
            
        
    
                
                                    Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/03/2025
            
            Locations: Snyder Building 480 Ray C. Hunt Drive, Charlottesville, Virginia         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis.
Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC).
Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                06/23/2025
            
            Locations: Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research, Miami, Florida         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    
                
                                    NAL ER IPF Respiratory Function and Safety Study
                                
            
            
        Recruiting
                            
            
                The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/16/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota  +1 locations         
        
        
            Conditions: Idiopathic Pulmonary Fibrosis
        
            
        
    1 - 12 of 24
            